Casgevy: How CRISPR-Edited Stem Cells Can Cure Sickle Cell Disease

Sickle cell disease is caused by a single typo in a gene — one that bends red blood cells into rigid sickle shapes that jam blood vessels and cause excruciating, life-shortening pain crises. For the first time in history, a therapy can essentially fix that at its source, by editing a patient's own stem cells with CRISPR. It's called Casgevy, and the trial results are genuinely extraordinary ¹. It's also one of the most demanding treatments in medicine — and being honest about both halves is what makes this a useful story rather than just a headline.

This is, by any measure, a landmark: one of the first approved therapies built on CRISPR gene editing, and a real-world demonstration that you can rewrite a disease at the level of the gene.

What question did the researchers ask?

The researchers asked whether editing a patient's own blood-forming stem cells could stop the severe pain crises that define sickle cell disease ¹.

The strategy is elegant. Before birth, we make fetal haemoglobin, which doesn't sickle; after birth, the body switches it off. Casgevy (also called exa-cel) collects a patient's own blood-forming (haematopoietic) stem cells and uses CRISPR-Cas9 to disable a genetic "off switch" (a region called BCL11A), so the cells start making fetal haemoglobin again. Those edited cells are then returned to the patient, where they repopulate the bone marrow and produce red cells that resist sickling. Because the cells are the patient's own, there's no rejection and no need for anti-rejection drugs — a key difference from donor therapies. Our stem-cell overview explains the blood-forming stem cells at the heart of this.

What did the trial find?

The results are about as strong as trial results get. Among patients with severe sickle cell disease — people who had been having multiple serious pain crises every year — the large majority were completely free of severe pain crises for at least 12 consecutive months after treatment ¹. Many were also freed from the repeated hospitalisations that had defined their lives.

For a disease that causes relentless pain, organ damage and shortened lifespan, that is not an incremental improvement — it's a functional cure for most who received it. On that strength, Casgevy was approved by regulators, becoming one of the first CRISPR-based medicines in history.

How strong is this evidence — and what's the catch?

The efficacy evidence is excellent. But the catch is the process, and it's substantial. To make room for the edited cells, patients first undergo harsh chemotherapy (myeloablative conditioning) to wipe out their existing bone marrow — which brings serious short-term risks, a long hospital stay, and fertility risks that often require planning ahead. The treatment is also extraordinarily expensive and available only at specialist centres.

There are honest open questions too: this is new, so the very long-term durability and safety (including any rare effects of gene editing) are still being followed. None of this diminishes the result — it contextualises it. Casgevy is a genuine, possibly curative therapy that is also one of the most intensive treatments a person can undergo, which is why it's reserved for severe disease.

What could this mean if you are considering treatment?

For people with severe sickle cell disease, Casgevy is a real, approved, potentially life-changing option — and a decision to weigh carefully with a specialist haematology team, because the benefits and the demands are both large. The questions worth asking: Am I eligible? What does the conditioning chemotherapy and recovery involve? What are the fertility implications and how are they managed? What's known about long-term follow-up?

It's also a reminder of scale: this is cutting-edge, hospital-based gene-and-cell therapy — the polar opposite of an outpatient "stem cell" infusion. The legitimacy here comes from rigorous trials and regulatory approval, not marketing.

What we see at the clinic

We don't deliver gene therapies like this, but people ask us how to make sense of "CRISPR cures" in the news. Our answer is that Casgevy is the real thing — genuine, approved, evidence-based regenerative medicine that can functionally cure a brutal disease — and that it's intensive, specialist treatment with serious trade-offs, delivered through major medical centres. We think it's one of the most hopeful stories in modern medicine, and exactly the standard against which lesser "stem cell" claims should be judged.

Common questions

Does Casgevy cure sickle cell disease? For most treated patients it functionally does — the large majority were free of severe pain crises for at least a year ¹. It's one of the first CRISPR-based therapies to achieve this.

Does it use donor cells? No — it edits the patient's own blood-forming stem cells, so there's no rejection and no anti-rejection drugs. But it does require harsh chemotherapy first.

Why isn't everyone with sickle cell getting it? Because it's intensive (chemotherapy conditioning, long hospital stay, fertility risks), very expensive, and available only at specialist centres — so it's reserved for severe disease.

[1] Exagamglogene Autotemcel for Severe Sickle Cell Disease. New England Journal of Medicine. 2024. https://pubmed.ncbi.nlm.nih.gov/38661449/

Key takeaway

Casgevy uses CRISPR to edit a patient's own blood-forming stem cells, switching fetal haemoglobin back on so red cells stop sickling — and in its trial, the large majority of people with severe sickle cell disease were freed from pain crises for at least a year. It's a genuine, possibly curative landmark and one of the first CRISPR medicines. The catch is real: harsh conditioning chemotherapy, fertility risks, huge cost and specialist-only access. A cure, earned the hard way.